MetaCap

Rapport Therapeutics (RAPP) vs UroGen Pharma (URGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

UroGen Pharma (URGN) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 6.9% versus a loss of 15.0%. Rapport Therapeutics is the larger company by market cap ($1.37 billion vs $1.36 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RAPP-15.01%URGN+6.88%
+101%+30%-41%
Nov 21, 20251 yearNov 20, 2026
RAPP+11.35%URGN+109.31%
+282%+98%-85%
Jun 3, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RAPP versus URGN key metrics
MetricRAPPURGN
Share price$23.16$27.65
Market cap$1.37B$1.36B
1-day change-1.82%-12.86%
YTD return-23.67%+18.06%
1-year return-15.01%+6.88%
5-year return—+127.76%
Forward P/E—11.08
EPS (TTM)$-3.17$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$109.79M
Revenue growth (YoY)—+21.45%
Net income (latest FY)$-111.48M$-153.49M
Gross margin—88.66%
Operating margin—-113.73%
Net margin—-139.81%
52-week high$52.93$50.81
52-week low$22.06$16.50
Distance from 52-week high-56.24%-45.58%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+177.25%+119.57%
Average volume790.62K1.11M
Shares outstanding59.28M49.05M
Employees84300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • URGN has outperformed RAPP by 21.9 percentage points over the past year.

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About UroGen Pharma

URGN stock →

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees

RAPP vs URGN FAQ

Which is bigger, Rapport Therapeutics or UroGen Pharma?

Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.37B compared with $1.36B for UroGen Pharma (URGN).

Which stock has performed better over the past year, RAPP or URGN?

URGN returned +6.88% over the past 12 months, compared with -15.01% for RAPP (price return, excluding dividends). Past performance does not predict future results.

Are Rapport Therapeutics and UroGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons